Immunomodulation of Kidney and Heart Transplants by Anti-idiotypic Antibodies
| Autor: | Mark A. Hardy, Eric A. Rose, Keith Reemtsma, Elaine F. Reed, Alan I. Benvenisty, Craig R. Smith, Nicole Suciu-Foca |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Pathology
medicine.medical_specialty Time Factors Human leukocyte antigen Antibodies Immune system Antigen Actuarial Analysis HLA Antigens medicine Humans Postoperative Period Kidney biology business.industry Graft Survival Kidney Transplantation Antibodies Anti-Idiotypic Survival Rate Transplantation surgical procedures operative medicine.anatomical_structure Monoclonal Immunology Anti-idiotypic antibodies biology.protein Heart Transplantation Surgery Antibody business Research Article Follow-Up Studies |
| Zdroj: | Annals of Surgery. 214:522-530 |
| ISSN: | 0003-4932 |
| DOI: | 10.1097/00000658-199110000-00016 |
| Popis: | To explore the possibility that circulating HLA antigens from the graft and anti-anti-HLA (anti-idiotypic) antibodies influence the long-term survival of renal and cardiac allografts, analysis of 330 renal allograft recipients and 174 recipients of cardiac allografts was conducted. Anti-donor-HLA antibodies (Ab1) present before or after transplantation are associated with graft failure, whereas irrelevant anti-HLA antibodies had no impact on actuarial graft survival. Ab1 may be uncovered by dissociation of immune complexes and depletion of soluble antigens with monoclonal antibody-coated magnetic beads. Of the 421 sera tested from 65 heart recipients, 97 showed Ab1 before depletion and 178 after depletion; similar rise in positive sera was seen in 39 renal transplant recipients. Three distinct patterns of appearance of Ab1 and Ab2 (anti-Ab1 antibody) were recognized. Patients with cyclic variations of Ab1 in association with Ab2 had 100% graft survival, whereas patients with cyclic variations of Ab1 but no detectable Ab2 had 2-year graft survival of 36% for kidneys and 71% for hearts. Presence of Ab1 in all sera after transplantation led to 47% and 56% 2-year renal and heart allograft survival, respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|